- Written by Carla Rothaus
Chronic migraine is a leading cause of disability worldwide. Expert opinion has been that patients with chronic migraine should receive preventive treatment; however, these treatments may be underused, not adhered to, associated with side effects, or ineffective. Silberstein et al. conducted a 16-week, double-blind, randomized, placebo-controlled, phase 3 trial with a 12-week active-intervention phase to evaluate the efficacy, safety, and side-effect profile of two dose regimens of fremanezumab (monthly and quarterly) for the preventive treatment of chronic migraine. Read the Original Article here .
Clinical Pearls
Q: What is the target of fremanezumab?
A: Fremanezumab…